JoanneLorraineBlumMDPhD
Oncology • Maple City, MIProfessor (Affiliated), Internal Medicine, TX A&M Univ Coll of Med Andy and Joan Horner Endowed Chair in Breast Cancer Research, BUMC, Retired as of 2/28/2022
Dr. Blum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2255 W School Lake Rd
Maple City, MI 49664Phone+1 469-767-1687- Is this information wrong?
Summary
- I am a board certified oncologist and trained at the University of Michigan. My practice was restricted to breast cancer. I was also the Director of the Hereditary Cancer Risk Program at the Baylor-Sammons Cancer Center at Baylor University Medical Center in Dallas, TX
Education & Training
University of MichiganPhD, Cellular and Molecular Biology, 1984 - 1987
University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 1983 - 1987- University of Michigan Health SystemResidency, Internal Medicine, 1980 - 1982
- Michael Reese Hospital and Medical CenterInternship, Internal Medicine, 1979 - 1980
University of Maryland School of MedicineClass of 1979- University of PennsylvaniaBA, Biology, Summa cum laude, 1971 - 1975
Certifications & Licensure
MI State Medical License 1981 - 2025
TX State Medical License 1988 - 2024
MD State Medical License 1979 - 1982- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Andy and Joan Horner Endowed Chair in Breast Cancer Research Baylor University Medical Center, Dallas, TS, 2016
- ASCO Clinical Trials Participation Award ASCO, 2008
- Distinguished Young Research Award University of Texas Southwestern Medical Center, 1990
- Join now to see all
Clinical Trials
- TAC Versus TC for Adjuvant Breast Cancer Start of enrollment: 2007 May 29
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Publications & Presentations
PubMed
- Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).Geyer, C., Blum, J., Yothers, G., Asmar, L., Flynn, P., Robert, N., Hopkins, J., O'Shaughnessy, J., Rastogi, P., Puhalla, S., Hilton, C., Dang, C., Gómez, H., Vukelja,...> ;Journal of Clinical Oncology. 2024 Feb 9
- Measures of functional status in older patients treated with palbociclib for advanced breast cancer.Cappelleri, J., Cuevas, J., Montelongo, M., Wang, Y., Karuturi, M., Blum, J., Patel, K., Telivala, B., McCune, S., Lakhanpal, S., Tripathy, D., Rocque, G.> ;Journal of Geriatric Oncology. 2024 Jan 1
- Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.Joanne L Blum, Caroline DiCristo, David Gordon, Meghan S Karuturi, David Oubre, Erin Jepsen, Juan Cuevas, Shailendra Lakhanpal, Monica Z Montelongo, Zhe Zhang, Joseph ...> ;Breast Cancer Research and Treatment. 2024 Feb 1
- Join now to see all
Journal Articles
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJoanne Blum, MD, The New England Journal of Medicine
Press Mentions
10 Dec COVID-19 Impacts Breast Cancer Study Data AcquisitionDecember 10th, 2020
Expert Shares Insight on Improved DFS with TaxAC in HER2-Negative Breast CancerJuly 5th, 2016
Anthracycline Regimen Superior in HER2-Negative Breast CancerJune 30th, 2016- Join now to see all
Grant Support
- Molecular Analyses of Breast Cancers from Individuals with Hereditary Cancer SyndromesBaylor Research Institute BRI and Translational Genomics Research Institute (TGen)2016–2018
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
